The structural determination of a transaction in the HealthTech and MedTech sectors, specifically the choice between a Share Purchase Agreement (SPA) and an Asset Purchase Agreement (APA), constitutes the most significant strategic pivot point for investors, founders and legal counsel. In an industry where valuation is predicated on a complex interplay of regulatory milestones, intellectual property (IP) robustness and high-fidelity patient data, the legal mechanism of transf